

# Ivermectin (STROMEKTOL) tablets

## Criteria for Use

### September 2021

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

*The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.*

The Product Information should be consulted for detailed prescribing information.

## Exclusion Criteria

**If the answer to ANY item below is met, then the patient should NOT receive ivermectin tablets.**

- ☐ Use as a treatment for COVID-19 infection without another appropriate indication (see inclusion criteria below)
- ☐ Known hypersensitivity to ivermectin
- ☐ Pregnancy

## Inclusion Criteria

**Prescribed by or in consultation with Infectious Diseases or other facility authorized provider(s) and at least ONE of the following**

- ☐ Treatment of a parasitic infection for which ivermectin is indicated (strongyloidiasis, onchocerciasis, lymphatic filariasis, cutaneous larva migrans, ascariasis, scabies and lice)
- ☐ Empiric treatment for *Strongyloides stercoralis* in a hospitalized patient at epidemiologic risk (birth, long-term residence in or travel to endemic locations) who is being initiated on corticosteroids or other immunosuppressant medications.

### Additional inclusion criteria for women of childbearing potential

- ☐ Pregnancy should be excluded prior to receiving ivermectin

## Supplemental Information

[A CDC Health Advisory \(8/26/21\)](#) discussed a study showing ivermectin dispensing from retail pharmacies increased 24 fold in August over the pre-pandemic baseline and that calls to poison control centers across the U.S. have increased five-fold in July of 2021.

[An FDA consumer update \(9/3/21\)](#) suggests against the use of ivermectin to treat or prevent COVID-19, mention that clinical trials do not show COVID-19 is effective, that large doses are dangerous and that products intended for animals are different from those in humans and should never be used on people.

For additional information, see the [National PBM Bulletin from 9/7/21](#)